Most Read Articles
Roshini Claire Anthony, 5 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

Stephen Padilla, 6 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
2 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 6 days ago
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.

NT-814 shows therapeutic potential in postmenopausal women with hot flashes

22 Mar 2020

Treatment with the dual neurokinin 1,3 antagonist NT-814 induces prompt, marked improvements in hot flashes and waking due to night sweats in postmenopausal women, with doses up to 300 mg being well tolerated, according to the results of a trial.

The trial randomized 76 postmenopausal women with moderate/severe hot flashes to receive 14 days of once-daily NT-814 (at 50, 100, 150 or 300 mg) or placebo. All women completed diaries of hot flash frequency and severity, as well as of waking due to night sweats, at baseline and during treatment.

All prespecified efficacy parameters (24-hour hot flash frequency and severity, frequency of waking due to night sweats) improved in all groups, even in placebo. At week 2, moderate/severe hot flash frequency decreased by a mean of 37 percent with placebo vs 24 percent with 50-mg (p=0.048), 59 percent with 100-mg (p=0.155), 84 percent with 150-mg (p<0.001) and 66 percent with 300-mg (p=0.022) NT-814.

Furthermore, the number of episodes of waking due to night sweats dropped by 32 percent in the placebo group vs 20 percent (p=0.059), 55 percent (p=0.135), 81 percent (p<0.001) and 63 percent (p=0.031) in the respective NT-814 dose-groups (50, 100,150 and 300 mg).

The improvements with NT-814 ≥150 mg occurred as early as the first week of treatment. Commonly reported treatment-related adverse events were mild somnolence and headache, observed frequently in the 300-mg group. Safety monitoring identified no concerns.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

Stephen Padilla, 6 days ago
Use of noninvasive ventilation (NIV), similar to invasive mechanical ventilation (IMV), appears to lessen mortality but may increase the risk for transmission of the novel coronavirus disease (COVID-19) in healthcare workers, suggest the results of a study.
2 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 6 days ago
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.